Diversify With These Health ETFs
The FDA recently approved higher-dose version of Novo Nordisk’s NVO obesity drug Wegovy, further expanding the drug giant’s footprint in…
Coming Soon: ‘Wegovy HD’
Federal regulators on Thursday approved a new higher-dose version of the blockbuster obesity drug Wegovy that may…
The Best Healthcare Stocks to Buy With $50 Right Now
It’s not hard to find healthcare stocks, including small-cap biotech companies, trading below $50 per share. However, many…
FDA sends letter to Novo Nordisk over potential GLP-1 side effects
The U.S. Food and Drug Administration sent a warning letter this month to Novo Nordisk, the maker of…
FDA sends letter to Novo Nordisk over potential GLP-1 side effects
The U.S. Food and Drug Administration sent a warning letter this month to Novo Nordisk, the maker of…
WHO Foundation and Novo Nordisk Expand Collaboration to Provide Financial Support towards strengthening health systems for Cardio-Renal-Metabolic Diseases
GENEVA, March 11, 2026 /PRNewswire/ — The WHO Foundation today announced an expanded collaboration with Novo Nordisk to support…
Weight-loss wegovy jab may carry greater risk of sudden sight loss, study finds – The Irish Times
Patients taking Wegovy have nearly five times the risk of sudden sight loss compared with those on Ozempic,…
Hims & Hers will sell real Ozempic in deal with Novo Nordisk
Hims & Hers and the Danish pharma giant Novo Nordisk have ended a bitter legal feud that will…
FDA warns Novo Nordisk over unreported potential Ozempic side effects
Novo Nordisk, the pharmaceutical company behind Ozempic, has received a warning letter from the U.S. Food and Drug…
The era of $199 copycat weight loss drugs is ending — and it could cost patients
After two splashy Super Bowl commercials focused on making weight loss medication more accessible, Hims & Hers will…
Ozempic, Wegovy list prices to be slashed by up to 50%
Weight loss drugmaker Novo Nordisk will cut the list prices of Ozempic and Wegovy by up to 50%…
1 Reason Why I’d Hold This Weight‑Loss Drug Leader Through Any Market Crash
Novo Nordisk (NYSE: NVO) and Eli Lilly (NYSE: LLY) are locked in a battle around GLP-1 weight-loss drugs.…